OnKure Therapeutics, Inc.(OKUR)
Biotechnology
Rare Disease / Orphan Drug
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership changeShares owned | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-24 | Leverone Jason A. Chief Financial Officer | Sale | -303 | -0.26%114,386 | $4.40 | $1,332 | View SEC filing | |
| 2026-06-24 | Saccomano Nicholas A President and CEO | Sale | -86 | -0.02%371,344 | $4.40 | $378 | View SEC filing | |
| 2026-03-24 | Leverone Jason A. Chief Financial Officer | Sale | -301 | -1.85%16,000 | $4.16 | $1,251 | View SEC filing | |
| 2026-03-24 | Saccomano Nicholas A President and CEO | Sale | -86 | -1.16%7,333 | $4.16 | $357 | View SEC filing | |
| 2025-12-23 | Leverone Jason A. Chief Financial Officer | Sale | -302 | -1.82%16,301 | $2.97 | $896 | View SEC filing | |
| 2025-12-23 | Saccomano Nicholas A President and CEO | Sale | -87 | -1.16%7,419 | $2.97 | $258 | View SEC filing | |
| 2025-09-24 | Leverone Jason A. Chief Financial Officer | Sale | -303 | -2.35%12,603 | $2.62 | $795 | View SEC filing | |
| 2025-09-24 | Saccomano Nicholas A President and CEO | Sale | -88 | -2.45%3,506 | $2.62 | $231 | View SEC filing | |
| 2025-06-25 | Saccomano Nicholas A President and CEO | Sale | -88 | -2.39%3,594 | $2.38 | $210 | View SEC filing | |
| 2025-06-25 | Leverone Jason A. Chief Financial Officer | Sale | -303 | -2.29%12,906 | $2.38 | $722 | View SEC filing | |
| 2025-05-19 | Hove Anders D 10% Owner | Purchase | +1,400,000 | +97.24%2,839,674 | $1.85 | $2,590,000 | View SEC filing | |
| 2025-05-19 | Cormorant Asset Management, LP Other | Sale | -1,813,439 | -100.00%0 | $1.85 | $3,363,023 | View SEC filing | |
| 2025-05-14 | Cormorant Asset Management, LP 10% Owner | Sale | -24,300 | -1.32%1,813,439 | $1.99 | $48,236 | View SEC filing | |
| 2025-04-08 | Saccomano Nicholas A President and CEO | Sale | -874 | -19.18%3,682 | $2.94 | $2,570 | View SEC filing | |
| 2025-04-08 | Leverone Jason A. Chief Financial Officer | Sale | -3,122 | -19.12%13,209 | $2.94 | $9,178 | View SEC filing | |
| 2024-09-26 | Leonard Braden Michael 10% Owner | Purchase | +98,346 | +2.25%4,478,164 | $1.47 | $144,738 | View SEC filing | |
| 2024-09-19 | Leonard Braden Michael 10% Owner | Purchase | +56,106 | +1.30%4,379,818 | $1.36 | $76,237 | View SEC filing | |
| 2024-09-16 | Leonard Braden Michael 10% Owner | Purchase | +358,923 | +9.05%4,323,712 | $1.35 | $484,344 | View SEC filing | |
| 2024-08-14 | Leonard Braden Michael 10% Owner | Purchase | +271,826 | +7.36%3,964,789 | $1.40 | $380,598 | View SEC filing | |
| 2024-05-16 | Leonard Braden Michael 10% Owner | Purchase | +414,281 | +12.64%3,692,963 | $1.54 | $639,578 | View SEC filing | |
| 2023-08-29 | Hall Ashley Chief Development Officer | Sale | -15,625 | -28.29%39,600 | $6.28 | $98,058 | View SEC filing | |
| 2023-06-23 | Novo Holdings A/S 10% Owner | Sale | -100,000 | -2.92%3,330,337 | $7.10 | $709,740 | View SEC filing | |
| 2023-05-10 | O'Donnell Niall Director | Purchase | +125,000 | +6.06%2,188,713 | $8.00 | $1,000,000 | View SEC filing | |
| 2022-09-02 | Cruse Michael Chief Operating Officer | Purchase | +7,500 | +121.03%13,697 | $3.39 | $25,448 | View SEC filing | |
| 2022-08-31 | Cruse Michael Chief Operating Officer | Purchase | +7,255 | +23.63%37,955 | $3.20 | $23,243 | View SEC filing |
1-25 of 41